trihexyphenidyl has been researched along with Dystonic Disorders in 18 studies
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.
Dystonic Disorders: Acquired and inherited conditions that feature DYSTONIA as a primary manifestation of disease. These disorders are generally divided into generalized dystonias (e.g., dystonia musculorum deformans) and focal dystonias (e.g., writer's cramp). They are also classified by patterns of inheritance and by age of onset.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trihexyphenidyl significantly improved dystonia, motor function and development in children with dystonic cerebral palsy in this study." | 8.31 | Trihexyphenidyl in young children with dystonic cerebral palsy: A single arm study. ( Das, B; Juneja, M; Khanna, R; Khosla, M; Mishra, D; Rajkumar, L; Sairam, S; Ventatakrishnan, A, 2023) |
| "We report 2 uncomplicated pregnancies in 1 woman with early-onset, sporadic, primary generalized dystonia (DYT1 negative) treated with high dosage trihexyphenidyl and review the literature on antidystonic agents and pregnancy." | 7.77 | Exposure to high dosage trihexyphenidyl during pregnancy for treatment of generalized dystonia: case report and literature review. ( Reich, SG; Robottom, BJ, 2011) |
| "Severe dystonia was presented in late stage of this disease." | 5.56 | Trihexyphenidyl for treatment of dystonia in ataxia telangiectasia: a case report. ( Jia, Y; Li, M; Qi, X; Wang, S; Wang, Y; Zhang, L, 2020) |
| "Trihexyphenidyl significantly improved dystonia, motor function and development in children with dystonic cerebral palsy in this study." | 4.31 | Trihexyphenidyl in young children with dystonic cerebral palsy: A single arm study. ( Das, B; Juneja, M; Khanna, R; Khosla, M; Mishra, D; Rajkumar, L; Sairam, S; Ventatakrishnan, A, 2023) |
| "Trihexyphenidyl (THP), a non-selective muscarinic receptor (mAChR) antagonist, is commonly used for the treatment of dystonia associated with TOR1A, otherwise known as DYT1 dystonia." | 4.12 | Blockade of M4 muscarinic receptors on striatal cholinergic interneurons normalizes striatal dopamine release in a mouse model of TOR1A dystonia. ( Donsante, Y; Downs, AM; Hess, EJ; Jinnah, HA, 2022) |
| "We report 2 uncomplicated pregnancies in 1 woman with early-onset, sporadic, primary generalized dystonia (DYT1 negative) treated with high dosage trihexyphenidyl and review the literature on antidystonic agents and pregnancy." | 3.77 | Exposure to high dosage trihexyphenidyl during pregnancy for treatment of generalized dystonia: case report and literature review. ( Reich, SG; Robottom, BJ, 2011) |
| "The majority (84%) had focal dystonia, most frequently cervical dystonia and blepharospasm." | 2.66 | Patient-reported responses to medical treatment in primary dystonia. ( Choi, JH; Jeon, B; Kim, HJ; Kim, R; Park, S; Shin, J; Woo, KA; Yoo, D, 2020) |
| "Severe dystonia was presented in late stage of this disease." | 1.56 | Trihexyphenidyl for treatment of dystonia in ataxia telangiectasia: a case report. ( Jia, Y; Li, M; Qi, X; Wang, S; Wang, Y; Zhang, L, 2020) |
| "Examination revealed dystonia of facial muscles every time she chewed but absent during drinking and speaking." | 1.46 | Chewing-induced facial dystonia: a rare presentation of task-specific dystonia. ( Garg, A; Kumar Rana, K; Kumawat, BL; Sharma, C, 2017) |
| "Case note review of 278 children with dystonia referred to our service." | 1.43 | Medication use in childhood dystonia. ( Kaminska, M; Lin, JP; Lumsden, DE; Tomlin, S, 2016) |
| "Here, we present a novel case of focal dystonia of a 51 years old right-handed woman who had developed difficulty in writing and performing fine motor tasks." | 1.39 | Focal dystonia of right hand with mirror movements upon use of left arm. ( Athar, A; Rana, AQ, 2013) |
| "DYT16 is an autosomal recessive dystonia-parkinsonism due to putative mutations at PRKRA gene." | 1.38 | DYT16: the original cases. ( Camargos, S; Cardoso, F; Lees, AJ; Singleton, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Downs, AM | 1 |
| Donsante, Y | 1 |
| Jinnah, HA | 1 |
| Hess, EJ | 1 |
| Rajkumar, L | 1 |
| Ventatakrishnan, A | 1 |
| Sairam, S | 1 |
| Khosla, M | 1 |
| Khanna, R | 1 |
| Das, B | 1 |
| Mishra, D | 1 |
| Juneja, M | 1 |
| Zhang, L | 1 |
| Jia, Y | 1 |
| Qi, X | 1 |
| Li, M | 1 |
| Wang, S | 1 |
| Wang, Y | 1 |
| Woo, KA | 1 |
| Kim, HJ | 1 |
| Yoo, D | 1 |
| Choi, JH | 1 |
| Shin, J | 1 |
| Park, S | 1 |
| Kim, R | 1 |
| Jeon, B | 1 |
| Sharma, C | 1 |
| Kumawat, BL | 1 |
| Garg, A | 1 |
| Kumar Rana, K | 1 |
| Patel, AS | 1 |
| Sulica, L | 1 |
| Frucht, SJ | 1 |
| Rana, AQ | 1 |
| Athar, A | 1 |
| van Vugt, FT | 1 |
| Boullet, L | 1 |
| Jabusch, HC | 2 |
| Altenmüller, E | 2 |
| Lumsden, DE | 1 |
| Kaminska, M | 1 |
| Tomlin, S | 1 |
| Lin, JP | 2 |
| Gika, AD | 1 |
| Hughes, E | 1 |
| Goyal, S | 1 |
| Sparkes, M | 1 |
| Verma, A | 1 |
| Yadav, R | 1 |
| Robottom, BJ | 1 |
| Reich, SG | 1 |
| Suzuki, K | 1 |
| Takano, M | 1 |
| Hashimoto, K | 1 |
| Numao, A | 1 |
| Nakamura, T | 1 |
| Sakuta, H | 1 |
| Hirata, K | 1 |
| Camargos, S | 1 |
| Lees, AJ | 1 |
| Singleton, A | 1 |
| Cardoso, F | 1 |
| BURNS, C | 1 |
| CORNER, BD | 1 |
| Baik, JS | 1 |
| Park, JH | 1 |
| Kim, JY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-Controlled, Double-Blind, Randomized, Cross Over Pilot Study Of The Efficacy And Tolerability Of Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand[NCT02107261] | Phase 2 | 21 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| A Placebo-controlled, Double-blind, Randomized, Cross Over Pilot Study of the Efficacy and Tolerability of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor[NCT03136341] | Phase 4 | 25 participants (Anticipated) | Interventional | 2018-12-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patient reported outcomes measured by questionnaires that address adverse events and the impact of quality of life using the perceived stress scale. A 10-item questionnaire, each item scored 0 (never) to 4 (very often), full scale from 0-40, with higher score indicating higher perceived stress. the more often the person perceives stress Change in PSS at week 8 compared to baseline (NCT02107261)
Timeframe: baseline and at 8 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.429 |
| XEOMIN | -0.5031 |
"Motor strength using a dynamometer of the finger/wrist/elbow flexors to document any treatment induced weakness.~Scale from 0-4, higher score indicates poorer health outcomes." (NCT02107261)
Timeframe: baseline and at 8 weeks
| Intervention | score on a scale (Least Squares Mean) | |
|---|---|---|
| Right FDP dig 2 | R Lumb dig 4 | |
| Placebo | 0.07 | -0.013 |
| XEOMIN | -0.087 | -0.1190 |
"Motor strength tested using a dynamometer to document any weakness the treatment may produce as compared to the baseline visit and 8 weeks.~Dynamometer (DYN) - is a mechanical device that measures the pounds of force that a muscle exerts, Grip - a device that measures grip strength, and finger flexors digit 2 and 3 (FF d2-3). These measures are the amount of lbs of force exert. The higher number is the highest exerted out of 3 tries." (NCT02107261)
Timeframe: baseline and at 8 weeks
| Intervention | lbs of force exert (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| DYN pnch 4 max | DYN pnch 4 avg | DYN pnch 3 max | DYN pnch 3 Avg | Grip max | Grip avg | FF D2-3 | |
| Placebo | 0.679 | 1.065 | 0.5570 | 1.1440 | 3.084 | 4.944 | 19.526 |
| XEOMIN | -3.037 | -2.323 | -2.905 | -2.2 | -25.04 | -22.172 | -4.423 |
The principal outcome measure was improvement in musical performance, measured by blinded rater, using physician global perception of change at post treatment compared to at 8 weeks. Categories are very much improved, much improved, minimal improved, no change, and minimal worse. (NCT02107261)
Timeframe: at visit 4 (week 8)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Very much improved | Much Improved | Minimally Improved | No Change | Minimally Worse | |
| Incobotulinum Toxin Injection | 1 | 4 | 3 | 0 | 1 |
| Placebo | 1 | 1 | 3 | 3 | 3 |
The principal outcome measure was improvement in musical performance, measured by blinded rater, using physician global perception of change at post treatment compared to at 8 weeks. Categories are very much improved, much improved, minimal improved, no change, and minimal worse. (NCT02107261)
Timeframe: at visit 4 (week 8)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Very much improved | Much Improved | Minimal Improved | No Change | Minimal Worse | |
| Incobotulinum Toxin Injection | 0 | 2 | 5 | 1 | 1 |
| Placebo | 0 | 1 | 4 | 3 | 3 |
"Rating of overall musical performance based on comparison to baseline video at week 8.~Rating from +3, very much improved to -3, very much worse. Higher score indicates more improvement." (NCT02107261)
Timeframe: baseline and at 8 weeks
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| +3 Very much improved | +2 Much improved | +1 Minimally improved | 0 No change | -1 Minimal worse | -2 Much worse | -3 Very much worse | |
| Placebo | 0 | 2 | 0 | 5 | 4 | 0 | 0 |
| XEOMIN | 1 | 2 | 3 | 2 | 1 | 0 | 0 |
"Rating of overall musical performance based on comparison to baseline video at week 8.~Best Overall Musical Performance on 7 point scale from +3 Very much improved to -3 Very much worse. Higher score indicates more improvement." (NCT02107261)
Timeframe: baseline and week 8
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| +3 Very much improved | +2 Much Improved | +1 Minimally Improved | 0 No Change | -1 Minimally Worse | -2 Much worse | -3 Very much worse | |
| Incobotulinum Toxin Injection | 0 | 2 | 4 | 2 | 1 | 0 | 0 |
| Placebo | 0 | 3 | 0 | 5 | 3 | 0 | 0 |
2 reviews available for trihexyphenidyl and Dystonic Disorders
| Article | Year |
|---|---|
Patient-reported responses to medical treatment in primary dystonia.
Topics: Baclofen; Benzodiazepines; Dystonic Disorders; Female; Humans; Levodopa; Male; Medical Records; Pati | 2020 |
Focal dystonia in musicians: phenomenology, pathophysiology, triggering factors, and treatment.
Topics: Botulinum Toxins, Type A; Drug Therapy, Combination; Dystonic Disorders; Education, Professional, Re | 2010 |
Focal dystonia in musicians: phenomenology, pathophysiology, triggering factors, and treatment.
Topics: Botulinum Toxins, Type A; Drug Therapy, Combination; Dystonic Disorders; Education, Professional, Re | 2010 |
Focal dystonia in musicians: phenomenology, pathophysiology, triggering factors, and treatment.
Topics: Botulinum Toxins, Type A; Drug Therapy, Combination; Dystonic Disorders; Education, Professional, Re | 2010 |
Focal dystonia in musicians: phenomenology, pathophysiology, triggering factors, and treatment.
Topics: Botulinum Toxins, Type A; Drug Therapy, Combination; Dystonic Disorders; Education, Professional, Re | 2010 |
16 other studies available for trihexyphenidyl and Dystonic Disorders
| Article | Year |
|---|---|
Blockade of M4 muscarinic receptors on striatal cholinergic interneurons normalizes striatal dopamine release in a mouse model of TOR1A dystonia.
Topics: Animals; Cholinergic Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dys | 2022 |
Trihexyphenidyl in young children with dystonic cerebral palsy: A single arm study.
Topics: Cerebral Palsy; Child; Child, Preschool; Dystonia; Dystonic Disorders; Humans; Infant; Motor Skills; | 2023 |
Trihexyphenidyl for treatment of dystonia in ataxia telangiectasia: a case report.
Topics: Ataxia Telangiectasia; Child; Dystonia; Dystonic Disorders; Humans; Male; Mutation; Phenotype; Trihe | 2020 |
Chewing-induced facial dystonia: a rare presentation of task-specific dystonia.
Topics: Dystonia; Dystonic Disorders; Face; Facial Muscles; Female; Humans; Mastication; Middle Aged; Tetrab | 2017 |
Velopharyngeal Dystonia: An Unusual Focal Task-specific Dystonia?
Topics: Adult; Cholinergic Antagonists; Dystonic Disorders; Female; Humans; Male; Middle Aged; Speech Disord | 2017 |
Focal dystonia of right hand with mirror movements upon use of left arm.
Topics: Dystonic Disorders; Female; Hand; Humans; Middle Aged; Treatment Outcome; Trihexyphenidyl | 2013 |
Musician's dystonia in pianists: long-term evaluation of retraining and other therapies.
Topics: Acupuncture Therapy; Adult; Antiparkinson Agents; Botulinum Toxins, Type A; Dystonic Disorders; Fema | 2014 |
Medication use in childhood dystonia.
Topics: Adolescent; Antiparkinson Agents; Baclofen; Child; Chloral Hydrate; Cohort Studies; Diazepam; Drug-R | 2016 |
Trihexyphenidyl for acute life-threatening episodes due to a dystonic movement disorder in Rett syndrome.
Topics: Adolescent; Antiparkinson Agents; Child; Dystonic Disorders; Electrocardiography; Electroencephalogr | 2010 |
Isolated lingual dystonia : responding to anticholinergic treatment.
Topics: Adult; Cholinergic Antagonists; Dystonic Disorders; Female; Humans; Speech; Tongue; Tongue Diseases; | 2011 |
Exposure to high dosage trihexyphenidyl during pregnancy for treatment of generalized dystonia: case report and literature review.
Topics: Adolescent; Adult; Antiparkinson Agents; Child; Child, Preschool; Dystonic Disorders; Female; Humans | 2011 |
Computer mouse-related dystonia: a novel presentation of task-specific dystonia.
Topics: Aged; Clonazepam; Computers; Cumulative Trauma Disorders; Dystonia; Dystonic Disorders; GABA Antagon | 2012 |
DYT16: the original cases.
Topics: Adolescent; Adult; Age of Onset; Anti-Dyskinesia Agents; Antiparkinson Agents; Baclofen; Biperiden; | 2012 |
Clumsy children.
Topics: Child; Conversion Disorder; Dystonia Musculorum Deformans; Dystonic Disorders; Genetic Diseases, X-L | 1963 |
Dystonia musculorum deformans in siblings; treated with artane (trihexyphenidyl).
Topics: Dystonia Musculorum Deformans; Dystonic Disorders; Genetic Diseases, X-Linked; Humans; Siblings; Tri | 1952 |
Primary lingual dystonia induced by speaking.
Topics: Antiparkinson Agents; Dystonic Disorders; Female; Humans; Middle Aged; Speech; Tongue; Trihexyphenid | 2004 |